Skip to main content

Ipsogen Licenses Affymetrix Array Technology for IVD Development

NEW YORK (GenomeWeb News) — Affymetrix today said that molecular diagnostic shop Ipsogen has signed a Powered by Affymetrix agreement, which gives it non-exclusive access to Affy’s array technology to develop and market in vitro diagnostic tests, initially for breast cancer, worldwide.
 
Financial details of the deal were not disclosed..

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.